S-1-containing chemotherapy for patients with non-small-cell lung cancer: A population-based observational study by the Ibaraki thoracic integrative (POSITIVE) research group

To evaluate the efficacy and safety of S-1 monotherapy, S-1-containing combined chemotherapy and S-1 containing chemoradiotherapy for non-small cell lung cancer (NSCLC), a population-based observational study was performed. The efficacy and safety of the chemotherapies were evaluated at 13 institute...

Full description

Saved in:
Bibliographic Details
Published in:Molecular and clinical oncology 2016-06, Vol.4 (6), p.1025-1030
Main Authors: INAGAKI, MASAHARU, SHINOHARA, YOKO, KABURAGI, TAKAYUKI, ENDO, TAKEO, HOMMA, SHINSUKE, HIZAWA, NOBUYUKI, KISHI, KOJI, NAKAMURA, HIROYUKI, HAYASHIHARA, KENJI, SAITO, TAKEFUMI, KURISHIMA, KOICHI, ISHIKAWA, HIROICHI, ICHIMURA, HIDEO, NAWA, TAKESHI, KIKUCHI, NORIHIRO, MIYAZAKI, KUNIHIKO, KODAMA, TAKAHIDE, SATOH, HIROAKI, FURUKAWA, KINYA
Format: Article
Language:English
Subjects:
Cancer
Cancer therapies
Chemotherapy
Clinical medicine
Clinical trials
Drug therapy
Epidermal growth factor
Lung cancer
Lung cancer, Non-small cell
Methods
Multivariate analysis
Mutation
non-small cell lung cancer
Observational studies
observational study
Oncology
Patient outcomes
Patients
Population
population-based
Population-based studies
S-1
Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To evaluate the efficacy and safety of S-1 monotherapy, S-1-containing combined chemotherapy and S-1 containing chemoradiotherapy for non-small cell lung cancer (NSCLC), a population-based observational study was performed. The efficacy and safety of the chemotherapies were evaluated at 13 institutes in a prefecture of Japan between April 2011 and March 2015. Datasets were obtained from 282 patients with NSCLC. For either wild-type or mutated epidermal growth factor receptor (EGFR), these three therapy groups generated almost identical response results and toxicity profiles as those in previously reported clinical trials, although the present study appeared to have slightly lower survival rates compared with those in the previous clinical trials. This may be due to the inclusion of patients in poor condition, and S-1 therapy being administered in the second, or later, line of therapy. In conclusion, the present study has confirmed that S-1-containing chemotherapy is effective against wild- and mutated-type EGFR NSCLC, and it is also tolerable in clinical practice.
ISSN:2049-9450
2049-9469
DOI:10.3892/mco.2016.826